
July 15, 2020

Listing Department

BSE Limited

P J Towers, Dalal Street, Fort,
Mumbai – 400001

Code: 532321

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated July 15, 2020 titled “Zydus starts the Human Dosing for Adaptive Phase I & II clinical trials”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors' at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI

COMPANY SECRETARY

Encl.: As above

Zydus starts human dosing of its vaccine ‘ZyCoV-D’

- Begins Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D
- *ZyCoV-D was found to be safe, immunogenic, well tolerated in the pre-clinical toxicity studies.*
- *The vaccine was able to elicit high level of neutralizing antibodies in animal studies.*

Ahmedabad, July 15, 2020

Zydus, an innovation driven global healthcare company, today announced that the Adaptive Phase I/ II human clinical trials of its plasmid DNA vaccine, ZyCoV-D commenced today with the first human dosing. The Adaptive Phase I/II dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine. The human dosing of the vaccine marks a key milestone since the launching of the accelerated vaccine development programme for COVID-19 in February 2020.

Speaking on the development, Chairman, Zydus Cadila, Mr. Pankaj R. Patel said, “This is an all important step in our fight against COVID-19. We acknowledge the support of National Biopharma Mission, BIRAC, Department of Biotechnology, Govt. of India and regulatory agencies ICMR and DGCI in the development of ZyCoV-D vaccine candidate. We look forward to the Adaptive Phase I/II clinical studies and gathering important data on ZyCoV-D in the months ahead.”

In the Adaptive Phase I/ II clinical trials, Zydus will be enrolling over 1000 subjects across multiple clinical study sites in India. The Company has already manufactured clinical GMP batches of the vaccine candidate for the clinical trials.

Zydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) developed at its Vaccine Technology Centre in Ahmedabad, India had successfully completed the preclinical phase and had received permission from the Drug Controller General of India - Central Drugs Standard Control Organisation (CDSCO) to initiate Adaptive Phase I/II human clinical trials in India.

About ZyCoV-D

In the pre-clinical phase, the vaccine was found to elicit a strong immune response in multiple animal species like mice, rats, guinea pigs and rabbits. The antibodies produced by the vaccine were able to neutralize the wild type virus in virus neutralization assay indicating the protective potential of the vaccine candidate. No safety concerns were observed for the vaccine candidate in repeat dose toxicology studies by both intramuscular and intradermal routes of administration. In rabbits, up to three times the intended human dose was found to be safe, well tolerated and immunogenic.

With ZyCoV-D, the Company has successfully established the DNA vaccine platform in the country using non-replicating and non-integrating plasmid carrying the gene of interest making it very safe. Further, no vector response and with absence of any infectious agent, the platform provides ease of manufacturing the vaccine with minimal biosafety requirements (BSL-1). The platform is also known to show much improved vaccine stability and lower cold chain requirements making it easy for transportation to remotest regions of the country. Furthermore, the platform can be rapidly used to modify the vaccine in couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines.

Zydus' Vaccine research programme

Vaccine Technology Centre of Zydus Cadila has wide range of capabilities in developing and manufacturing viral, toxoid, polysaccharide, conjugate and other subunit vaccines for unmet needs. In fact, Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat Swine Flu during the pandemic in 2010. In past, it has also indigenously developed numerous vaccines successfully including tetravalent seasonal influenza vaccine (first company in India to indigenously develop and commercialize), Inactivated Rabies vaccine (WHO Prequalified), Varicella vaccine (first Indian company to indigenously develop and receive market authorization), Measles containing vaccines (MR, MMR, Measles), Typhoid conjugate vaccine, pentavalent vaccine (DPT-HepB-Hib) etc to name a few. The company also has a strong pipeline of vaccines like Measles-Mumps-Rubella-Varicella (MMRV), Human papillomavirus vaccine, Hepatitis A, Hepatitis E vaccines which are at various stages of development.